TriSalus Life Sciences Inc. recently released an investor presentation outlining its 2025 outlook and upcoming milestones. The company highlights its Pressure Enabled Drug Delivery (PEDD) infusion technology, which aims to improve drug delivery for solid tumors, particularly in liver and pancreatic cancers. TriSalus projects significant market opportunities, with a potential $2.5 billion device market and additional revenue from the potential approval of Nelitolimod, a TLR9 agonist, for pancreatic cancer. The company anticipates a 50% revenue growth and plans to launch TriNav XP for Uterine Fibroid Embolization in Q4 2025. TriSalus also boasts a robust intellectual property portfolio, with 79 registered patents expiring between 2030-2040 and 95 pending applications. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.